Klin Farmakol Farm. 2014;28(2):65-67

The place of leflunomide in the treatment of active rheumatoid arthritis

David Suchý, Jan Voříšek

Oddělení klinické farmakologie FN Plzeň

The biological, pharmacological and therapeutic properties of leflunomide in the treatment of rheumatoid arthritis (RA) are reviewed.

Leflunomide alone, or in combination with other antirheumatic drugs, is an effective and potent immunosuppressant developed

for the treatment of moderate to severe RA. Leflunomide can be used as a first-line DMARD in patients with RA who cannot tolerate

methotrexate or in whom the drug is contraindicated. The addition of leflunomide to methotrexate in patients with RA who do not respond

adequately to methotrexate monotherapy can help improve disease activity control. Leflunomide may be used in combination

with anti-TNF and other biological agents, with its effectiveness being comparable to treatment with the combination of methotrexate

plus an anti-TNF or another biologic agent. Common adverse events include diarrhoea, nausea, vomiting, rash, alopecia, and minor

infections. Major adverse events include significant lung injury, severe infection, and cytopenia. The risk of adverse events is increased

with concurrent medication, particularly methotrexate, alcohol consumption, and a low body weight.

Keywords: leflunomide, pharmacology, rheumatoid arthritis

Published: July 1, 2014  Show citation